Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

The current interest in prodrugs is evident. Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the ...

Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA ...